First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.
about
Aptamers in TherapeuticsAptamers: A Feasible Technology in Cancer ImmunotherapyAptamer-nanoparticle complexes as powerful diagnostic and therapeutic tools.From selection hits to clinical leads: progress in aptamer discoveryAptamers in diagnostics and treatment of viral infectionsA Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1Structural basis for specific inhibition of Autotaxin by a DNA aptamerModulation of the Coagulation Cascade Using AptamersFunctional display of platelet-binding VWF fragments on filamentous bacteriophageTechniques for molecular imaging probe designProgress in molecular imaging in endoscopy and endomicroscopy for cancer imaging.Recent Progress in Nucleic Acid Aptamer-Based Biosensors and Bioassays.Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy.Novel therapies in the pipeline: Directions of research into platelet inhibitionThrombotic microangiopathies: multimers, metalloprotease, and beyond.Targeting von Willebrand factor and platelet glycoprotein Ib receptor.Investigational drugs in thrombotic thrombocytopenic purpura.The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitusVWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.The chimeric monoclonal antibody MHCSZ-123 against human von Willebrand factor A3 domain inhibits high-shear arterial thrombosis in a Rhesus monkey modelAptamers: from bench side research towards patented molecules with therapeutic applications.Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.The crystal structure of the active domain of Anopheles anti-platelet protein, a powerful anti-coagulant, in complex with an antibody.Triggers, targets and treatments for thrombosis.Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.Nucleic acid aptamers: clinical applications and promising new horizonsIdentification of a small molecule that modulates platelet glycoprotein Ib-von Willebrand factor interactionAnti-heparanase aptamers as potential diagnostic and therapeutic agents for oral cancer.Development of universal antidotes to control aptamer activity.von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse modelsRational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies.Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitorEffects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.Newer agents in antiplatelet therapy: a review.In situ Protein Detection for Companion Diagnostics.Aptamer-based therapeutics: new approaches to combat human viral diseasesThe chemical biology of aptamers.
P2860
Q26738413-B5975548-4226-4141-A563-FE689DC18FC9Q26740303-E0216D06-A2DA-42B4-89CF-508E2833C481Q26752263-4CEECA31-ADF7-425C-AA76-E415A306F45FQ26752799-EB2E156B-1196-4BC4-843C-5C2641456DDBQ27014527-A8B64045-10C9-4F94-B455-C38006F88416Q27658166-5AD773E9-D29B-44A0-8833-202EC4C28FECQ27704519-AD73F1AF-6D6B-409E-AA12-F065B446E64AQ28816936-A640701C-10BA-41C3-87C5-52A640017642Q30353471-851D12B5-5BAC-4A26-8A80-1CEAD72885A5Q30423734-9BB7C7FF-D703-4EC0-AB95-49D43399D51AQ30426514-AC1484F0-9DA2-4E71-AA2E-F33193B101B4Q30448290-55CDF603-3C2C-447B-845B-ADFDF5F553F4Q30498050-663B256B-024E-445D-B9E2-0D82BB331349Q30498119-05FDCA90-4A5E-4CE6-A4A6-725068AC74E5Q33353375-40F765C9-90F6-4D8F-BE38-9697B689AC44Q33389435-DE0E5F1B-60C2-4F61-8290-BDFE0F84E2CDQ33392975-5F1AB0B6-5F24-44A8-AE13-CA18745F645AQ33395696-58571249-489F-40C7-964D-9A80CDB675A3Q33405692-36CDF1E5-00CA-44E7-9389-49C221CBEE33Q33419324-B4E8BF5F-18AA-4381-9212-ED6B6EADC56FQ33441990-DF3A3C38-929A-4484-99F8-FD7B9A2C2523Q33512089-DA990264-502B-4063-9E0D-56176848705EQ33685876-1750F5D7-8C32-4FF4-B7F1-0B6D0A48A6B9Q33718529-531433AD-ED39-4D72-AE44-E0044D68C35DQ33765444-61630D02-22BB-43EA-8E61-AF6ECC1C532FQ33901933-B119701F-51EC-4636-8768-7F5AB7ABAFDCQ34028112-36C7C7B2-40AA-4166-9F61-B064AE048E00Q34122627-76459DD6-35BB-4DCD-B140-A6E802F14F8BQ34306827-BE64C139-9607-4EA5-A9E3-87F9D5C52122Q34433842-E7BCBBAA-F3CA-4677-AD0C-79E4B4A5CE04Q34666946-4190803A-8854-4429-AEDA-E0F1769DD285Q35413768-75085279-1CC6-4118-B284-119153D6A4E9Q35536246-ACEA5E1B-0306-4758-ADC6-311D447FAD0CQ35671956-939A8B15-BAE9-4FB2-9280-822FCE71F875Q35750010-45F99289-E332-49A8-9350-31EDD8DE889DQ35757741-6DDE1809-54AD-44C0-9E69-21D147BB8883Q36085620-CDB71BDA-CE5A-4BB3-A860-10DF1C5B843FQ37270405-5DF2C62F-B3F9-41D5-A0E6-DC0576123E01Q37415958-76761724-7C69-4CDF-9485-99A0AE2C0F1FQ37423243-3A1E6222-A7CC-4A1D-ADB9-F603EE1A2724
P2860
First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
First-in-human evaluation of a ...... ARC1779 in healthy volunteers.
@en
type
label
First-in-human evaluation of a ...... ARC1779 in healthy volunteers.
@en
prefLabel
First-in-human evaluation of a ...... ARC1779 in healthy volunteers.
@en
P2093
P1433
P1476
First-in-human evaluation of a ...... ARC1779 in healthy volunteers.
@en
P2093
Christopher J Horvath
H Nicholas Marsh
James C Gilbert
Judith M Healy
Patricia G Merlino
Renta M Hutabarat
Robert G Schaub
Sleiman Boufakhreddine
Thomas V Holohan
Tia DeFeo-Fraulini
P304
P356
10.1161/CIRCULATIONAHA.107.724864
P407
P577
2007-11-19T00:00:00Z